Redx Pharma logo

REDX - Redx Pharma Share Price

66p 0.0  0.0%

Last Trade - 4:23pm

Sector
Healthcare
Size
Small Cap
Market Cap £180.8m
Enterprise Value £173.7m
Revenue £5.69m
Position in Universe 854th / 1807
Bullish
Bearish
Unlock REDX Revenue
Momentum
Relative Strength (%)
1m -0.84%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -30.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Sep 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 30.5 0.13 3.13 5.69 10.4 10.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 September 2020, RedxPharma PLC revenues increased 82% to £5.7M. Net lossincreased from £4.3M to £9.2M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsRecovery of derecognised asset decrease from £869K (income)to £0K, Share based compensation increase from £45K to£568K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for REDX
Graphical History

Revenue

REDX Revenue Unlock REDX Revenue

Net Income

REDX Net Income Unlock REDX Revenue

Normalised EPS

REDX Normalised EPS Unlock REDX Revenue

PE Ratio Range

REDX PE Ratio Range Unlock REDX Revenue

Dividend Yield Range

REDX Dividend Yield Range Unlock REDX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
REDX EPS Forecasts Unlock REDX Revenue
Profile Summary

Redx Pharma Plc, is engaged in drug discovery, pre-clinical development and licensing. It is engaged in drug discovery across cancer, infection and autoimmune diseases. It has over three programs like Porcupine RXC004 is a combination with PD-1 / PD-L1 in solid tumor (colorectal cancer), GI-targeted ROCK is focused on Crohn’s disease, Porcupine (REDX06109) is focused on Idiopathic pulmonary fibrosis (IPF), ROCK2 selective is focused on Non-alcoholic Steatohepatitis (NASH) and research in Validated targets (SHP2, AZ collaboration and undisclosed targets) focused in Cancer & Fibrosis which has reached candidate nomination stage. Its anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX004, is a class of antibiotic acting through the type II bacterial topoisomerases.

Directors
Last Annual September 30th, 2020
Last Interim September 30th, 2020
Incorporated September 7, 2010
Public Since March 27, 2015
No. of Shareholders: n/a
No. of Employees: 52
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange London Stock Exchange (AIM)
Shares in Issue 273,887,213
Free Float (0.0%)
Eligible for
ISAs
SIPPs
REDX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for REDX
Upcoming Events for REDX
Frequently Asked Questions for Redx Pharma
What is the Redx Pharma share price?

As of 4:23pm, shares in Redx Pharma are trading at 66p, giving the company a market capitalisation of £180.8m. This share price information is delayed by 15 minutes.

How has the Redx Pharma share price performed this year?

Shares in Redx Pharma are currently trading at 66p and the price has moved by 0.700k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Redx Pharma price has moved by 0.676k% over the past year.

What are the analyst and broker recommendations for Redx Pharma?

Of the analysts with advisory recommendations for Redx Pharma, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Redx Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Redx Pharma next release its financial results?

Redx Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Redx Pharma dividend yield?

Redx Pharma does not currently pay a dividend.

Does Redx Pharma pay a dividend?

Redx Pharma does not currently pay a dividend.

When does Redx Pharma next pay dividends?

Redx Pharma does not currently pay a dividend.

How do I buy Redx Pharma shares?

To buy shares in Redx Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Redx Pharma?

Shares in Redx Pharma are currently trading at 66p, giving the company a market capitalisation of £180.8m.

Where are Redx Pharma shares listed? Where are Redx Pharma shares listed?

Here are the trading details for Redx Pharma:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: REDX
What kind of share is Redx Pharma?

Based on an overall assessment of its quality, value and momentum, Redx Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Redx Pharma share price forecast 2021?

Shares in Redx Pharma are currently priced at 66p. At that level they are trading at 1.52% premium to the analyst consensus target price of 65.01.

Analysts covering Redx Pharma currently have a consensus Earnings Per Share (EPS) forecast of -0.078 for the next financial year.

How can I tell whether the Redx Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Redx Pharma. Over the past six months, the relative strength of its shares against the market has been 4.28%. At the current price of 66p, shares in Redx Pharma are trading at 33.89% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Redx Pharma PE Ratio?

We were not able to find PE ratio data for Redx Pharma.

Who are the key directors of Redx Pharma?

Redx Pharma's management team is headed by:

Neil Murray - FDR
Derek Lindsay - COO
Norman Molyneux - NED
Peter Jackson - CFD
Peter McPartland - NED
Simon Thorn - SEC
Bernhard Kirschbaum - NED
Iain Ross - NEC
Lisa Anson - CEO
James Mead - CFO
Thomas Burt - NED
Jane Robertson - OTH
Who are the major shareholders of Redx Pharma?

Here are the top five shareholders of Redx Pharma based on the size of their shareholding:

Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 79.55% (217.9m shares)
Sofinnova Crossover I SLP Corporation
Percentage owned: 9.41% (25.8m shares)
Polar Capital LLP Investment Advisor/Hedge Fund
Percentage owned: 4.96% (13.6m shares)
Polar Capital Funds Plc - Healthcare Opportunities Fund Mutual Fund
Percentage owned: 4.96% (13.6m shares)
Edwards (Graham Henry) Individual Investor
Percentage owned: 1.46% (4.00m shares)
Similar to REDX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.